- Company
- Rising status of antidiabetic SGLT-2 inhibitors
- by Jul 26, 2022 06:05am
- SGLT-2 inhibitors made an external growth of 16% in the first half of this year. SGLT-2 inhibitors, which were first approved as a type 2 diabetes treatment, expanded into the field of heart failure and made over &8361;80 billion in prescriptions in the first half of the year. Being recently recommended as a major treatment option in treat
- Company
- Keytruda indication has been expanded
- by Jul 26, 2022 06:05am
- The immuno-cancer drug Keytruda has expanded its treatment indication to early triple negative breast cancer following metastaticity. With the addition of Keytruda to adjuvant therapy before and after surgery, it is expected to contribute to reducing the recurrence rate by using immuno-cancer drugs early. MSD Korea held a press conference at
- Company
- Evusheld can be prescribed in Korea
- by Eo, Yun-Ho Jul 26, 2022 06:05am
- COVID-19 preventive drug Evusheld has begun preparing for actual prescriptions. According to related industries, AstraZeneca's Evusheld passed the Drug Committee of 200 medical institutions nationwide, including the Big 5 Advanced General Hospitals such as Seoul National University Hospital and Samsung Medical Center through the Korea Centers
- Company
- EC market, occupied more than 70% of Bayer and Hyundai
- by Nho, Byung Chul Jul 25, 2022 05:58am
- In the emergency contraceptive market worth 15 billion won, Hyundai Pharmaceutical and Bayer have a market share of more than 70%, effectively dominating the market. Bayer Mirena has performed in the 6 billion won range for loop-type emergency contraceptives, and Hyundai's Norebwon and Ellaone have performed in the 5 billion won range for eme
- Company
- He Young Lee appointed new head of BMS Korea
- by Eo, Yun-Ho Jul 25, 2022 05:57am
- He Young Lee, the current Country Manager of Viatris Korea, has been appointed the new head of BMS Korea. According to industry sources, BMS Korea had carried out the recruitment process after the current General Manager (46), Jinyoung Kim, was transferred to the Global Compliance Organization, after which He Young Lee was nominated as th
- Company
- Heart failure guidelines revised for the first time in 6 yrs
- by Jul 25, 2022 05:57am
- The clinical practice guidelines for heart failure have been completely revised for the first time in 6 years. The new guideline contains all the latest drugs ranging from SGLT-2 inhibitors that demonstrated an effect in heart failure, angiotensin receptor-neprilysin inhibitors (ARNIs) that are represented by the Entresto, to the recently approv
- Company
- How will the prescription market react?
- by Chon, Seung-Hyun Jul 25, 2022 05:57am
- Pharmaceutical companies are also paying keen attention to the rapid increase in the number of COVID-19 confirmed cases this month. Since the spread of COVID-19 in the past two years, the prescription market seems to be closely watching recent changes in the situation. According to the Central Disease Control Headquarters of the Korea Centers
- Company
- Strong dollar slows sales of Epis’s 3 biosimilars in Europe
- by Jul 22, 2022 05:53am
- The 3 autoimmune disorder biosimilars developed by Samsung Bioepis (Benepali, Imraldi, Flixabi) made slower sales in Europe in the first half of this year. Total sales fell by 4.7% compared to the previous year. Sales of the products had suffered a hard blow from the recent strong dollar and the continued pressure to cut prices. According
- Company
- Takeda's anti-cancer drug Exkivity has been approved
- by Jul 22, 2022 05:53am
- A second targeted anticancer drug targeting EGFR Exxon 20 insertion mutation has emerged. Takeda Pharmaceutical Korea announced on the 20th that it has received approval from the Ministry of Food and Drug Safety for the EGFR Exxon 20 insertion mutant non-small cell lung cancer treatment Exkivity (Mobocertinib). Exkivity is a TKI that inhib
- Company
- Imbruvica makes 4th attempt to extend reimbursement
- by Eo, Yun-Ho Jul 21, 2022 06:04am
- Already for the fourth time, Janssen is attempting to expand reimbursement for ‘Imbruvica’ as a first-line treatment. According to industry sources, reimbursement of Imbruvica (ibrutinib) as a first-line treatment for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Leukemia (SLL) will once again be deliberated by the Health Ins
